# Impact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach

Bruno Polack, Myriam Thomas, Alejandra Wu-Chuang, Lianet Abuin-Denis, Alejandro Cabezas-Cruz, Elsa Jacouton, Mohamed Mammeri, Isabelle Florent, Luis G Bermúdez-Humarán

► To cite this version:

Bruno Polack, Myriam Thomas, Alejandra Wu-Chuang, Lianet Abuin-Denis, Alejandro Cabezas-Cruz, et al.. Impact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach. Parasites & Vectors, 2026, 19 (1), pp.22. 10.1186/s13071-025-07166-3. hal-05460556

HAL Id: hal-05460556

https://hal.science/hal-05460556v1

Submitted on 15 Jan 2026

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
BRIEF REPORT

Open Access

<figure><img src="image_2.png" /></figure>

# Impact of *Lactobacillus johnsonii* CNCM I-4884 on canine giardiasis: a probiotic-based approach

Bruno Polack<sup>1†</sup>, Myriam Thomas<sup>1†</sup>, Alejandra Wu-Chuang<sup>1</sup>, Lianet Abuin-Denis<sup>1</sup>, Alejandro Cabezas-Cruz<sup>1</sup>,
Elsa Jacouton<sup>2</sup>, Mohamed Mammeri<sup>1</sup>, Isabelle Florent<sup>3*</sup> and Luis G. Bermúdez-Humarán<sup>2*</sup>

**Abstract**

This study reports a new therapeutic approach for canine giardiasis, the most common intestinal protozoan infection caused by *Giardia intestinalis*. It is based on the use of the probiotic strain *Lactobacillus johnsonii* CNCM I-4884 and, in particular, its bile salt hydrolase enzymatic activities. Clinical trials in dogs demonstrated that daily administration of *L. johnsonii* CNCM I-4884 significantly reduced *Giardia* cyst shedding after 14 days. These results highlight the potential of this probiotic as a promising alternative to antimicrobials, such as nitroimidazoles or benzimidazoles, for the treatment of giardiasis in dogs. Moreover, they provide a novel approach for the veterinary industry to develop innovative products targeting this parasite. In addition to its direct anti-*Giardia* effect, *L. johnsonii* CNCM I-4884 may also act as an adjuvant therapy, supporting intestinal homeostasis, enhancing host defense mechanisms, and promoting recovery of gut balance during or after antiparasitic treatments. This dual role suggests that the strain could be considered not only as a complementary therapy but, in specific cases, as a potential stand-alone probiotic treatment for canine giardiasis.

**Keywords** *Lactobacillus johnsonii*, Probiotics, *Giardia intestinalis*, Giardiasis, Dogs

*Giardia intestinalis* is a protozoan parasite that causes giardiasis, a common intestinal infection affecting humans and mammals worldwide [1]. Symptoms of giardiasis include diarrhea, abdominal pain, weight loss, and malabsorption, although infections are frequently

asymptomatic [2]. *G. intestinalis* is classified into eight genetic groups, known as assemblages, with the following host preference: A and B (humans and other mammals, zoonotic), C and D (canids), E (ungulates), F (felines), G (rodents), and H (pinnipeds) [3]. However, these assemblages are not strictly host specific; canine genotypes have been observed in humans as well as in ruminants and pigs, and assemblages A, B, and F have also been found in dogs [3, 4].

Two recent meta-analysis studies estimated that the prevalence of giardiasis in dogs was, respectively, 13% [5] and 15.2% [6]. Nevertheless, this prevalence was nearly three times higher before 6 months of age than after and twice as high in strays/kennel dogs as in pet dogs [7]. The main treatments for *G. intestinalis* infections are benzimidazoles and nitroimidazoles. However, treatment failures are increasingly common, affecting 5-50% of

<footnote>†Bruno Polack and Myriam Thomas have contributed equally to this work.</footnote>

<footnote>*Correspondence:
Isabelle Florent
isabelle.florent@mnhn.fr
Luis G. Bermúdez-Humarán
luis.bermudez@inrae.fr</footnote>

<footnote n="1">¹ Laboratoire de Santé Animale, Anses, INRAE, Ecole Nationale Vétérinaire d'Alfort, UMR BIPAR, 94700 Maisons-Alfort, France</footnote>

<footnote n="2">² Micalis Institute, Domain de Vilvert, Université Paris-Saclay, INRAE, AgroParisTech, 78350 Jouy-en-Josas, France</footnote>

<footnote n="3">³ UMR 7245, Muséum National d'Histoire Naturelle, Centre National de La Recherche Scientifique, Sorbonne Universités, 75005 Paris, France</footnote>
cases, partly owing to the emergence of drug-resistant strains over the last 15 years [5, 6, 8, 9]. This growing resistance highlights the need for alternative therapeutic strategies.

Probiotics have emerged as a promising alternative for the prevention and treatment of giardiasis [10]. Our recent studies have demonstrated that the probiotic strain *Lactobacillus johnsonii* CNCM I-4884 can inhibit the growth of *G. intestinalis* both in vitro and in vivo using a murine model of giardiasis [11]. This protective effect is mostly mediated by bile salt hydrolase (BSH) enzymes, which convert conjugated bile acids into unconjugated forms that are toxic to the parasite [12, 13]. On the basis of this discovery, we patented a new therapeutic approach to fight giardiasis.

In this study, we validated the potential of this probiotic strain for veterinary use through a clinical trial in young Beagle dogs naturally infected with *G. intestinalis*. The animals were randomly selected, and initial infection was confirmed by centrifugal flotation with zinc sulfate and a positive IDEXX SNAP® Giardia Test (SNAP-Giardia SNAP® Giardia™, Idexx, France) 3 days before the experiment (D-3). Only healthy dogs excreting *Giardia* were included; prior treatments

involved fenbendazole 2 weeks before D-3 and toltrazuril 3–4 days after weaning, with coproscopy confirming absence of other parasites. Dogs remained asymptomatic throughout the study to avoid ethical issues associated with treating sick animals, and no clinical signs requiring intervention occurred.

Before the trial, we optimized laboratory-scale production and storage conditions for the probiotic strain. Comparing freeze-dried and frozen preparations with glycerol, we found glycerol freezing to best preserve bacterial viability. The probiotic was then administered orally for 14 days at 1 × 10¹⁰ colony forming units (CFU)/ day to 20 naturally infected puppies (mean age 7.2 weeks; 20 males, 20 females). A placebo group (n=20) received glycerol alone under identical conditions. Fecal samples were collected individually at days 0, 4, 7, 11, and 14 post treatment, either refrigerated at 4 °C for cyst counting or frozen at -80 °C for quantitative polymerase chain reaction (qPCR) and microbiota analysis. *Giardia* cysts were quantified using direct immunofluorescence assays (DIF) with MeriFluor® *Cryptosporidium/Giardia* (Meridian Bioscience, Italy), the international gold standard for cyst and trophozoite detection (see Fig. 1 for more detail). The study design allowed assessment of the

The characteristics of the trial were as follows:

<figure><img src="image_3.png" /><figcaption>**Fig. 1** Characteristics of the clinical trial and experimental strategy. Created in BioRender. Bermudez, L. (2025) https://BioRender.com/614o83o</figcaption></figure>
probiotic anti-*Giardia* effect while maintaining ethical
standards and scientific validity.

Briefly, 1 g aliquots of fresh fecal samples were diluted
in 10 mL distilled water and filtered through three layers
of surgical gauze. DIF assays were then performed in
duplicate using 20 µL of this solution with Merifluor®
Cryptosporidium/Giardia kit (Meridian Bioscience,
Italy). Whole slides were examined under a fluorescent
microscope with 20× objective. As shown in Fig. 2A, G.
intestinalis cyst counts showed a significant reduction
in cyst numbers in the probiotic-treated group at days
7, 11, and 14 compared with the control group. In
addition, the level of bacterial species L. johnsonii was
determined by qPCR with the primers: Rw_ AGCATC
TGTTTCCAGGTGTTATCC; Fw_ AGTCGAGCG
AGCTAGCCTAGATG as previously described [14]. To
quantify and normalize the data, we used the delta cycle
threshold (CT) method with CT values obtained with the
following primers: Rw_ CGCCACTGGTGTTCYTCC
ATATA; Fw_ AGCAGTAGGGAATCTTCCA [14] as
reference gene. The results were normalized according to
the weight of the fecal extract used for DNA extraction.
Statistical analysis was performed using GraphPad
Prism software (version 5) and a nonparametric Mann-
Whitney statistical test. As shown in Fig. 2B, L. johnsonii
species were detected in both groups (placebo and
probiotic) at all sampling times. However, at day 0, no
significant differences were observed between the two
groups. Nonetheless, at the end of the study (day 14),
the probiotic-treated group (B) exhibited a significant
increase in the abundance of this species compared with
the control group (A) (P=0.0059). This increase aligns
with the daily intake of the strain in the probiotic group.

In addition, fecal samples at two different time points
(D0 and D14) were sequenced to determine the impact
of our probiotic administration on gut microbiota

composition. Raw sequences were de-interlaced,
de-multiplexed, and processed in QIIME2 [15] using
DADA2 [16] for de-noising and merging of reads.
Amplicon sequence variants were aligned with MAFFT
[17], and a phylogenetic tree was constructed with
FastTree [18]. Taxonomic classification was performed
using a naïve Bayes classifier trained on the SILVA 138
database [19]. Alpha and beta diversity indexes were
calculated with the q2-diversity plugin in the QIIME2
environment. Alpha diversity analysis showed that both
Shannon entropy (Fig. 3A) and Faith's phylogenetic
diversity (Fig. 3B) did not differ significantly between
the probiotic-treated and placebo control groups. In
contrast, beta diversity analysis revealed that probiotic
treatment led to changes in the bacterial community
composition and abundance, compared with the other
three experimental groups, as measured by the Jaccard
index (Fig. 3C, PERMANOVA, *q*<0.05) and Bray-
Curtis dissimilarity (Fig. 3D, PERMANOVA, *q*<0.05).
Taxa abundance differences were evaluated using the
ALDEx2 package in R. Only the abundance of the taxon
Escherichia–Shigella was significantly different among
the different groups (Fig. 3E). Specifically, the abundance
of Escherichia–Shigella was significantly higher in the
probiotic-treated group at day 14 compared with the
same group at day 0 (Fig. 3E, Kruskal–Wallis, *q*<0.05).
However, the abundance of Escherichia–Shigella at day
14 was not significantly different from the placebo group
at the same day (Fig. 3E, Kruskal–Wallis, *q*>0.05).

In conclusion, our findings demonstrate that the
probiotic strain *L. johnsonii* CNCM I-4884 is effective
in controlling giardiasis in naturally infected dogs. This
probiotic-based approach could serve as a valuable
complement to existing registered drugs such as
benzimidazole and metronidazole in the management
of this widespread parasitic disease. In addition, gut

<figure><img src="image_4.png" /><figcaption>**Fig. 2 A** Enumeration of *G. intestinalis* cysts in fecal samples after probiotic treatment. Values are mean ± standard error of the mean (SEM). **B** Levels of *L. johnsonii* in the feces of puppies treated with probiotics or placebo (*P* < 0.05, ***P* < 0.001)</figcaption></figure>
<figure><img src="image_5.png" /><figcaption>**Fig. 3** Probiotic impact on gut microbiota. Alpha diversity of the microbiota was measured using **A** Shannon entropy and **B** Faith phylogenetic indexes in dogs treated with probiotic compared with the placebo group. Beta diversity of dog microbiota was analyzed with **C** Jaccard, and **D** Bray-Curtis dissimilarity indexes to measure the similarity between the bacterial communities in probiotic compared with the placebo control group. **E** CLR values of the taxon *Escherichia-Shigella* whose abundance changed significantly between different treatment groups</figcaption></figure>

microbiota analysis revealed that the efficacy of the probiotic is accompanied by changes in gut microbiota composition, including an increase in the *Escherichia-Shigella* taxon in treated dogs. An increase in *Escherichia* within the gut microbiota may be beneficial to the host, particularly when the strain is nonpathogenic, as it could help maintain a balanced microbial ecosystem or participate in competitive exclusion. For example, the probiotic *Escherichia coli* Nissle 1917 has been shown to reduce intestinal colonization by *Salmonella enterica Typhimiurium* by competing for iron [20]. Whether *Escherichia* plays a role in the observed reduction of *Giardia* in this study remains to be investigated. It is noteworthy, however, that the increase of *Escherichia-Shigella* abundance at day 14 was observed in both the probiotic-treated and placebo groups, suggesting that this change in abundance could be due to factors related to age or environment and not necessarily to the probiotic treatment.

Beyond its direct anti-*Giardia* activity, the use of *L. johnsonii* CNCM I-4884 may also provide secondary

benefits to the host by modulating gut microbiota
composition, enhancing mucosal defense mechanisms,
and supporting recovery of gut homeostasis during
or after antiparasitic therapy. Such adjuvant effects
underline its potential as a complementary intervention
alongside standard treatments, and in certain cases, as a
promising stand-alone therapeutic option.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13071-025-07166-3.

Supplementary Material 1.

**Acknowledgments**

Data supporting the main conclusions of this study are included in
the manuscript.

**Author contributions**

Conceptualization, B.P., I.F., and L.G.B.-H.; Methodology, B.P., M.T., A.W.-C., L.A.-D., A.C.-C., S.G., and E.J.; Software, A.W.-C., L.A.-D., and A.C.-C.; Validation, B.P., A.C.-C., I.F., and L.G.B.-H.; Formal analysis, B.P., A.C.-C., I.F., and L.G.B.-H.; Investigation, B.P., M.T., A.W.-C., L.A.-D., A.C.-C., and S.G.; Resources, B.P., I.F., and L.G.B.-H.; Data
curation, B.P., M.T., A.C.-C., I.F., and L.G.B.-H; Writing—original draft preparation, B.P., I.F., and L.G.B.-H; Writing—review and editing, B.P., A.C.-C., I.F., and L.G.B.-H; Supervision, B.P., I.F., and L.G.B.-H; Project administration, B.P., I.F., and L.G.B.-H; Funding acquisition, L.G.B.-H. All authors have read and agreed to the published version of the manuscript.

### Funding

This research was funded by prematurity PoC in labs program (Université Paris-Saclay, 2016–2018) and Agence Nationale de la Recherche [grant no. ANR-23-CE18-0022].

### Data availability

Data supporting the main conclusions of this study are included in the manuscript.

## Declarations

### Ethics approval and consent to participate

The clinical trial was performed under the approval and oversight of the local ethical committee for clinical research of the Ecole Nationale Vétérinaire d'Alfort (approval no. ComERC 2017-10-20).

### Competing interests

A.C.-C. and L.G.B.-H. are co-founders of microXpace. The other authors declare no competing interests.

### Consent for publication

All authors provide this consent.

Received: 29 July 2025 Accepted: 14 November 2025

Published online: 06 December 2025

## References

1. Cernikova L, Faso C, Hehl AB. Five facts about *Giardia lamblia*. PLoS Pathog. 2018;14:e1007250. https://doi.org/10.1371/journal.ppat.1007250.

2. Adam RD. *Giardia duodenalis*: biology and pathogenesis. Clin Microbiol Rev. 2021;34:e0002419. https://doi.org/10.1128/CMR.00024-19.

3. Caccio SM, Lalle M, Svard SG. Host specificity in the *Giardia duodenalis* species complex. Infect Genet Evol. 2018;66:335–45. https://doi.org/10.1016/j.meegid.2017.12.001.

4. Silva A, Martins FDC, Ladeia WA, Kakimori MTA, Lucas JI, Sasse JP, et al. First report of Giardia duodenalis assemblage F in humans and dogs in southern Brazil. Comp Immunol Microbiol Infect Dis. 2022;89:101878. https://doi.org/10.1016/j.cimid.2022.101878.

5. Arguello-Garcia R, Leitsch D, Skinner-Adams T, Ortega-Pierres MG. Drug resistance in *Giardia*: mechanisms and alternative treatments for giardiasis. Adv Parasitol. 2020;107:201–82. https://doi.org/10.1016/bs.apar.2019.11.003.

6. Lalle M, Hanevik K. Treatment-refractory giardiasis: challenges and solutions. Infect Drug Resist. 2018;11:1921–33. https://doi.org/10.2147/IDR.S141468.

7. Bouzid M, Halai K, Jeffreys D, Hunter PR. The prevalence of *Giardia* infection in dogs and cats, a systematic review and meta-analysis of prevalence studies from stool samples. Vet Parasitol. 2015;207:181–202. https://doi.org/10.1016/j.vetpar.2014.12.011.

8. Morch K, Hanevik K. Giardiasis treatment: an update with a focus on refractory disease. Curr Opin Infect Dis. 2020;33:355–64. https://doi.org/10.1097/QCO.0000000000000668.

9. Kaufmann H, Zenner L, Benabed S, Poirel MT, Bourgoin G. Lack of efficacy of fenbendazole against *Giardia duodenalis* in a naturally infected population of dogs in France. Parasite. 2022;29:49. https://doi.org/10.1051/parasite/2022048.

10. Travers MA, Florent I, Kohl L, Grellier P. Probiotics for the control of parasites: an overview. J Parasitol Res. 2011;101:610769. https://doi.org/10.1155/2011/610769.

11. Allain T, Chaouch S, Thomas M, Travers MA, Valle I, Langella P, et al. Bile salt hydrolase activities: a novel target to screen anti-*Giardia lactobacilli*? Front Microbiol. 2018;9:89. https://doi.org/10.3389/fmicb.2018.00089.

12. Travers MA, Sow C, Zirah S, Deregnaucourt C, Chaouch S, Queiroz RM, et al. Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic *Lactobacillus johnsonii* La1 inhibit *Giardia duodenalis* in vitro growth. Front Microbiol. 2016;7:1453. https://doi.org/10.3389/fmicb.2016.01453.

13. Allain T, Chaouch S, Thomas M, Valle I, Buret AG, Langella P, et al. Bile-salt-hydrolases from the probiotic strain *Lactobacillus johnsonii* La1 mediate anti-giardial activity in vitro and in vivo. Front Microbiol. 2017;8:2707. https://doi.org/10.3389/fmicb.2017.02707.

14. Mayeur C, Gratadoux JJ, Bridonneau C, Chegdani F, Larroque B, Kapel N, et al. Faecal D/L lactate ratio is a metabolic signature of microbiota imbalance in patients with short bowel syndrome. PLoS ONE. 2013;8:e54335. https://doi.org/10.1371/journal.pone.0054335.

15. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Galith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852–7. https://doi.org/10.1038/s41587-019-0209-9.

16. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3. https://doi.org/10.1038/nmeth.3869.

17. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002;30:3059–66. https://doi.org/10.1093/nar/gkf436.

18. Price MN, Dehal PS, Arkin AP. FastTree 2—Approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5:e9490. https://doi.org/10.1371/journal.pone.0009490.

19. Yarza P, Yilmaz P, Pruesse E, Glockner FO, Ludwig W, Schleifer KH, et al. Uniting the classification of cultured and uncultured bacteria and archaea using 16S rRNA gene sequences. Nat Rev Microbiol. 2014;12:635–45. https://doi.org/10.1038/nrmicro3330.

20. Deriu E, Liu JZ, Pezeshki M, Edwards RA, Ochoa RJ, Contreras H, et al. Probiotic bacteria reduce *Salmonella typhimurium* intestinal colonization by competing for iron. Cell Host Microbe. 2013;14:26–37. https://doi.org/10.1016/j.chom.2013.06.007.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;

2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;

3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;

4. use bots or other automated methods to access the content or redirect messages

5. override any security feature or exclusionary protocol; or

6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer Nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com